ADARx Pharmaceuticals, Inc. Filed Primary

What the company does

ADARx Pharmaceuticals is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The company is advancing a pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs, with the goal of controlling the expression of specific disease drivers through highly selective RNA-targeted therapies. Leveraging two proprietary technologies—messenger RNA Silencing Technology (MST) and Cell Targeted Delivery (CTD)—ADARx seeks to optimize siRNA sequences and delivery to both hepatic and extrahepatic tissues, prioritizing chronic diseases where deep, durable target suppression can deliver meaningful clinical benefit for patients with significant unmet need. The company was incorporated under the laws of the State of Delaware in December 2019 and is headquartered in San Diego, California.

Use of proceeds

The company intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments, to advance the development of agazisiran (including completion of Phase 2 and advancement of Phase 3 clinical development in complement-mediated diseases), to advance the development of onvuzosiran (including completion of the Phase 3 STOP-HAE trial and pre-commercial activities), to advance the development of ADX-626 (including completion of its Phase 1a trial and advancement of a Phase 2 trial for secondary stroke prevention), to advance the ADX-077 and ADX-199 programs (including Phase 1 trials), and the remainder for additional research and development efforts on current and future therapeutic candidates and for working capital and other general corporate purposes.

Underwriters

Extracted from S-1 0001193125-26-383838, filed Sep 4, 2026 and verified against that filing text.

Key risk factors

• Significant losses and no profitability

  “We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.”